Kevin Coleman BS, PhD

Kevin Coleman leads an experimental pharmacology group at TESARO that is focused on mechanism-of-action and efficacy studies designed to support the advancement of TESARO’s small molecule and biologics cancer pipeline. Prior to TESARO, Kevin held a series of drug discovery and management positions with Arvinas, Merck, Pfizer, and BMS. He earned his BS in Biology at University of Connecticut, his Ph.D. in Cellular and Molecular Biology at the University of Michigan, and conducted his postdoctoral studies in the Department of Biochemistry and Biophysics at the University of California, San Francisco.